Drug intelligence / Profile preview

BI 1584862

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 1584862 is an orally bioavailable small molecule drug candidate developed by Boehringer Ingelheim for the treatment of geographic atrophy, a form of dry age-related macular degeneration. The drug is currently in Phase II clinical trials for this indication. Its precise mechanism of action has not been disclosed or defined publicly. Clinical studies are ongoing to assess its safety, tolerability, and efficacy in adults with geographic atrophy[1][3][4][5].

Targets

CYP11B2 (Cytochrome P450 11B2)

Beyond the preview

Go deeper on BI 1584862.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1584862.

Explore the full profile